Therapy Protocol
177Lu-DOTA therapy – 150 to 200 mCi
Lutetium-177 DOTATATE peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumours (NETs).
Dose: 150-200 mCi
Indication: Neuroendocrine
Clinical Overview & Mechanism
Lutetium-177 DOTATATE (PRRT) is an FDA & EMA-approved targeted peptide receptor radionuclide therapy for NETs.
Have questions about this therapy?
Book a consultation with Dr. Nikunj Jain for personalized treatment planning and expert guidance.